{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T02:45:41Z","timestamp":1785725141014,"version":"3.56.0"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100029020","name":"Alvah and Wyline Chapman Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100029020","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007028","name":"Leona M. and Harry B. Helmsley Charitable Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007028","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA268513"],"award-info":[{"award-number":["CA268513"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.canlet.2026.218689","type":"journal-article","created":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T06:13:12Z","timestamp":1781935992000},"page":"218689","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Orthogonally targeted tumor radiosensitization using cell penetrating peptide-ATM inhibitor conjugates to stimulate anti-tumor immune responses"],"prefix":"10.1016","volume":"657","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6267-0312","authenticated-orcid":false,"given":"Kanika","family":"Dhawan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M.","family":"Allevato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Lesperance","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria F.","family":"Camargo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5404-8132","authenticated-orcid":false,"given":"Marcus M.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahsa","family":"Mortaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bamdad","family":"Zareh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina V.","family":"Hingorani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen R.","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Silvio","family":"Gutkind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7964-1315","authenticated-orcid":false,"given":"Sunil J.","family":"Advani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.canlet.2026.218689_bib1","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/nrd4003","article-title":"Strategies for optimizing the response of cancer and normal tissues to radiation","volume":"12","author":"Moding","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.canlet.2026.218689_bib2","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ctrv.2016.03.001","article-title":"Optimize and refine therapeutic index in radiation therapy: overview of a century","volume":"45","author":"Chargari","year":"2016","journal-title":"Cancer Treat Rev."},{"issue":"2","key":"10.1016\/j.canlet.2026.218689_bib3","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/ncponc0714","article-title":"The concurrent chemoradiation paradigm--general principles","volume":"4","author":"Seiwert","year":"2007","journal-title":"Nat. Clin. Pract. Oncol."},{"issue":"5","key":"10.1016\/j.canlet.2026.218689_bib4","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol."},{"issue":"24","key":"10.1016\/j.canlet.2026.218689_bib5","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJM199106133242402","article-title":"Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer","volume":"324","author":"Department of Veterans Affairs Laryngeal Cancer Study","year":"1991","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.canlet.2026.218689_bib6","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1200\/JCO.1998.16.4.1310","article-title":"Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099","volume":"16","author":"Al-Sarraf","year":"1998","journal-title":"J. Clin. Oncol."},{"issue":"24","key":"10.1016\/j.canlet.2026.218689_bib7","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1056\/NEJM199206113262403","article-title":"Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus","volume":"326","author":"Herskovic","year":"1992","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.canlet.2026.218689_bib8","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1200\/JCO.1999.17.9.2692","article-title":"Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer","volume":"17","author":"Furuse","year":"1999","journal-title":"J. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.canlet.2026.218689_bib9","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa1106106","article-title":"Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer","volume":"366","author":"James","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"28","key":"10.1016\/j.canlet.2026.218689_bib10","doi-asserted-by":"crossref","first-page":"4620","DOI":"10.1200\/JCO.2006.06.7629","article-title":"Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203","volume":"24","author":"Gerard","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.canlet.2026.218689_bib11","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1056\/NEJM199904153401501","article-title":"Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer","volume":"340","author":"Morris","year":"1999","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.canlet.2026.218689_bib12","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nrc3007","article-title":"Strategies to improve radiotherapy with targeted drugs","volume":"11","author":"Begg","year":"2011","journal-title":"Nat. Rev. Cancer"},{"issue":"10","key":"10.1016\/j.canlet.2026.218689_bib13","doi-asserted-by":"crossref","first-page":"e501","DOI":"10.1016\/S1470-2045(24)00199-2","article-title":"Best practices and novel approaches for the preclinical development of drug-radiotherapy combinations for cancer treatment","volume":"25","author":"Prasanna","year":"2024","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.canlet.2026.218689_bib14","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41698-025-00885-x","article-title":"Spatially precise chemo-radio-immunotherapy by antibody drug conjugate directed tumor radiosensitization to potentiate immunotherapies","volume":"9","author":"Mortaja","year":"2025","journal-title":"npj Precis. Oncol."},{"issue":"13","key":"10.1016\/j.canlet.2026.218689_bib15","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1158\/1078-0432.CCR-13-3229","article-title":"Molecular pathways: overcoming radiation resistance by targeting DNA damage response pathways","volume":"21","author":"Morgan","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"173","key":"10.1016\/j.canlet.2026.218689_bib16","doi-asserted-by":"crossref","first-page":"173sr2","DOI":"10.1126\/scitranslmed.3005148","article-title":"New paradigms and future challenges in radiation oncology: an update of biological targets and technology","volume":"5","author":"Liauw","year":"2013","journal-title":"Sci. Transl. Med."},{"issue":"11","key":"10.1016\/j.canlet.2026.218689_bib17","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.2217\/fon.11.111","article-title":"DNA damage response and repair: insights into strategies for radiation sensitization of gliomas","volume":"7","author":"Kesari","year":"2011","journal-title":"Future Oncol."},{"issue":"10","key":"10.1016\/j.canlet.2026.218689_bib18","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1093\/hmg\/7.10.1555","article-title":"ATM: from gene to function","volume":"7","author":"Rotman","year":"1998","journal-title":"Hum. Mol. Genet."},{"issue":"5","key":"10.1016\/j.canlet.2026.218689_bib19","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1080\/095530096145535","article-title":"The ATM gene and the radiobiology of ataxia-telangiectasia","volume":"69","author":"Jorgensen","year":"1996","journal-title":"Int. J. Radiat. Biol."},{"issue":"6922","key":"10.1016\/j.canlet.2026.218689_bib20","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nature01368","article-title":"DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation","volume":"421","author":"Bakkenist","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218689_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.118137","article-title":"ATM inhibitors in cancer radiotherapy: mechanisms, clinical development, and future directions","volume":"300","author":"Al-Zoubi","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"6","key":"10.1016\/j.canlet.2026.218689_bib22","doi-asserted-by":"crossref","first-page":"eaat1719","DOI":"10.1126\/sciadv.aat1719","article-title":"The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models","volume":"4","author":"Durant","year":"2018","journal-title":"Sci. Adv."},{"issue":"1","key":"10.1016\/j.canlet.2026.218689_bib23","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1158\/1535-7163.MCT-18-1394","article-title":"Pharmacology of the ATM inhibitor AZD0156: potentiation of irradiation and olaparib responses preclinically","volume":"19","author":"Riches","year":"2020","journal-title":"Mol. Cancer Therapeut."},{"issue":"10","key":"10.1016\/j.canlet.2026.218689_bib24","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1093\/jnci\/djt055","article-title":"Opportunities and challenges in the era of molecularly targeted agents and radiation therapy","volume":"105","author":"Lin","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"issue":"4","key":"10.1016\/j.canlet.2026.218689_bib25","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1158\/1078-0432.CCR-23-1129","article-title":"A phase Ib study of the DNA-PK inhibitor peposertib combined with neoadjuvant chemoradiation in patients with locally advanced rectal cancer","volume":"30","author":"Romesser","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.canlet.2026.218689_bib26","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.ijrobp.2023.09.024","article-title":"A phase 1 study of the DNA-PK inhibitor peposertib in combination with radiation therapy with or without cisplatin in patients with advanced head and neck tumors","volume":"118","author":"Samuels","year":"2024","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"5","key":"10.1016\/j.canlet.2026.218689_bib27","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1158\/1078-0432.CCR-20-2551","article-title":"Phase I and pharmacologic study of olaparib in combination with high-dose radiotherapy with and without concurrent cisplatin for non-small cell lung cancer","volume":"27","author":"de Haan","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"20","key":"10.1016\/j.canlet.2026.218689_bib28","doi-asserted-by":"crossref","first-page":"4949","DOI":"10.1158\/1078-0432.CCR-18-0467","article-title":"Final report of a phase I trial of olaparib with cetuximab and radiation for heavy smoker patients with locally advanced head and neck cancer","volume":"24","author":"Karam","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"6382","key":"10.1016\/j.canlet.2026.218689_bib29","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.canlet.2026.218689_bib30","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","article-title":"Immune checkpoint therapy-current perspectives and future directions","volume":"186","author":"Sharma","year":"2023","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.canlet.2026.218689_bib31","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1667\/RR15121.1","volume":"190","author":"Falls","year":"2018","journal-title":"Radiat. Res."},{"key":"10.1016\/j.canlet.2026.218689_bib32","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Vanpouille-Box","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218689_bib33","doi-asserted-by":"crossref","DOI":"10.4161\/onci.28518","article-title":"Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death","volume":"3","author":"Golden","year":"2014","journal-title":"Oncoimmunology"},{"issue":"7547","key":"10.1016\/j.canlet.2026.218689_bib34","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nature14292","article-title":"Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer","volume":"520","author":"Twyman-Saint Victor","year":"2015","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.canlet.2026.218689_bib35","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1091\/mbc.e08-08-0805","article-title":"Polarized traffic of LRP1 involves AP1B and SNX17 operating on Y-dependent sorting motifs in different pathways","volume":"20","author":"Donoso","year":"2009","journal-title":"Mol. Biol. Cell"},{"issue":"8","key":"10.1016\/j.canlet.2026.218689_bib36","doi-asserted-by":"crossref","first-page":"e352","DOI":"10.1016\/S1470-2045(24)00075-5","article-title":"Radiotherapy, immunity, and immune checkpoint inhibitors","volume":"25","author":"Lynch","year":"2024","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.canlet.2026.218689_bib37","doi-asserted-by":"crossref","first-page":"e240","DOI":"10.1016\/S1470-2045(18)30096-2","article-title":"Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American society for radiation oncology","volume":"19","author":"Bristow","year":"2018","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.canlet.2026.218689_bib38","doi-asserted-by":"crossref","first-page":"3926","DOI":"10.1172\/JCI96519","article-title":"ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation","volume":"128","author":"Vendetti","year":"2018","journal-title":"J. Clin. Investig."},{"issue":"1","key":"10.1016\/j.canlet.2026.218689_bib39","doi-asserted-by":"crossref","first-page":"6923","DOI":"10.1038\/s41467-024-51236-6","article-title":"Sculpting the tumour microenvironment by combining radiotherapy and ATR inhibition for curative-intent adjuvant immunotherapy","volume":"15","author":"Patin","year":"2024","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.canlet.2026.218689_bib40","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2217\/imt-2018-0111","article-title":"Enhancing tumor T cell infiltration to enable cancer immunotherapy","volume":"11","author":"Zhang","year":"2019","journal-title":"Immunotherapy"},{"issue":"9","key":"10.1016\/j.canlet.2026.218689_bib41","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007474","article-title":"ATM inhibition augments type I interferon response and antitumor T-cell immunity when combined with radiation therapy in murine tumor models","volume":"11","author":"Jin","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"19","key":"10.1016\/j.canlet.2026.218689_bib42","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas","volume":"363","author":"Younes","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.canlet.2026.218689_bib43","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody-drug conjugates come of age in oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"issue":"7","key":"10.1016\/j.canlet.2026.218689_bib44","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1158\/0008-5472.CAN-14-1931","article-title":"Tumor radiosensitization by monomethyl auristatin E: mechanism of action and targeted delivery","volume":"75","author":"Buckel","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218689_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.120032","article-title":"Redirecting extracellular proteases to molecularly guide radiosensitizing drugs to tumors","volume":"248","author":"Hingorani","year":"2020","journal-title":"Biomaterials"},{"issue":"3","key":"10.1016\/j.canlet.2026.218689_bib46","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13030365","article-title":"Tumor activated cell penetrating peptides to selectively deliver immune modulatory drugs","volume":"13","author":"Hingorani","year":"2021","journal-title":"Pharmaceutics"},{"issue":"23","key":"10.1016\/j.canlet.2026.218689_bib47","doi-asserted-by":"crossref","DOI":"10.3390\/molecules29235618","article-title":"Tumor-targeted cell-penetrating peptides reveal that monomethyl auristatin E temporally modulates the tumor immune microenvironment","volume":"29","author":"Mortaja","year":"2024","journal-title":"Molecules"},{"issue":"6","key":"10.1016\/j.canlet.2026.218689_bib48","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1158\/1535-7163.MCT-13-1067","article-title":"Dual targeting of integrin alphavbeta3 and matrix metalloproteinase-2 for optical imaging of tumors and chemotherapeutic delivery","volume":"13","author":"Crisp","year":"2014","journal-title":"Mol. Cancer Therapeut."},{"issue":"5\u20136","key":"10.1016\/j.canlet.2026.218689_bib49","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1039\/b904878b","article-title":"Systemic in vivo distribution of activatable cell penetrating peptides is superior to that of cell penetrating peptides","volume":"1","author":"Aguilera","year":"2009","journal-title":"Integr. Biol."},{"issue":"51","key":"10.1016\/j.canlet.2026.218689_bib50","doi-asserted-by":"crossref","first-page":"17867","DOI":"10.1073\/pnas.0408191101","article-title":"Tumor imaging by means of proteolytic activation of cell-penetrating peptides","volume":"101","author":"Jiang","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.canlet.2026.218689_bib51","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1038\/s41467-022-31601-z","article-title":"Monomethyl auristatin antibody and peptide drug conjugates for trimodal cancer chemo-radio-immunotherapy","volume":"13","author":"Hingorani","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218689_bib52","article-title":"Interactions of antibody drug conjugate anti-tubulin and topoisomerase I inhibitor payloads with radiotherapy to potentiate immunotherapy","author":"Lesperance","year":"2025","journal-title":"Adv. Sci. (Weinh.)"},{"issue":"1","key":"10.1016\/j.canlet.2026.218689_bib53","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1021\/bc0502917","article-title":"Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity","volume":"17","author":"Doronina","year":"2006","journal-title":"Bioconjug. Chem."},{"issue":"7578","key":"10.1016\/j.canlet.2026.218689_bib54","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/nature16057","article-title":"Novel antibody-antibiotic conjugate eliminates intracellular S. aureus","volume":"527","author":"Lehar","year":"2015","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.canlet.2026.218689_bib55","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1038\/nchem.2635","article-title":"Targeted drug delivery through the traceless release of tertiary and heteroaryl amines from antibody-drug conjugates","volume":"8","author":"Staben","year":"2016","journal-title":"Nat. Chem."},{"issue":"15","key":"10.1016\/j.canlet.2026.218689_bib56","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1158\/0008-5472.CAN-19-0761","article-title":"Inhibition of ATM increases interferon signaling and sensitizes pancreatic cancer to immune checkpoint blockade therapy","volume":"79","author":"Zhang","year":"2019","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.canlet.2026.218689_bib57","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1158\/1078-0432.CCR-18-1821","article-title":"ATR inhibition potentiates the radiation-induced inflammatory tumor microenvironment","volume":"25","author":"Dillon","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.canlet.2026.218689_bib58","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.168824","article-title":"Potentiating the radiation-induced type I interferon antitumoral immune response by ATM inhibition in pancreatic cancer","volume":"9","author":"Zhang","year":"2024","journal-title":"JCI Insight"},{"issue":"5\u20136","key":"10.1016\/j.canlet.2026.218689_bib59","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1039\/b904890a","article-title":"In vivo characterization of activatable cell penetrating peptides for targeting protease activity in cancer","volume":"1","author":"Olson","year":"2009","journal-title":"Integr. Biol."},{"issue":"16","key":"10.1016\/j.canlet.2026.218689_bib60","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1039\/C8CS00676H","article-title":"Cleavable linkers in antibody-drug conjugates","volume":"48","author":"Bargh","year":"2019","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.canlet.2026.218689_bib61","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3389\/fimmu.2019.00193","article-title":"Role of radiation therapy in modulation of the tumor stroma and microenvironment","volume":"10","author":"Menon","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218689_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2022.153941","article-title":"Natural citrus flavanone 5-demethylnobiletin stimulates melanogenesis through the activation of cAMP\/CREB pathway in B16F10 cells","volume":"98","author":"Wang","year":"2022","journal-title":"Phytomedicine"},{"issue":"2","key":"10.1016\/j.canlet.2026.218689_bib63","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1172\/JCI67313","article-title":"Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice","volume":"124","author":"Deng","year":"2014","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.canlet.2026.218689_bib64","doi-asserted-by":"crossref","DOI":"10.1177\/15353508241245265","article-title":"Combining nuclear medicine with other modalities: future prospect for multimodality imaging","volume":"23","author":"Archibald","year":"2024","journal-title":"Mol. Imaging"},{"issue":"26","key":"10.1016\/j.canlet.2026.218689_bib65","doi-asserted-by":"crossref","DOI":"10.3748\/wjg.v31.i26.109500","article-title":"Serum exosomal hsa-let-7f-5p: a potential diagnostic biomarker for metastatic pancreatic cancer detection","volume":"31","author":"Ren","year":"2025","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.canlet.2026.218689_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102788","article-title":"Circulating tumor DNA-based assessment of molecular residual disease in non-metastatic melanoma","volume":"129","author":"De Simoni","year":"2024","journal-title":"Cancer Treat Rev."},{"issue":"1","key":"10.1016\/j.canlet.2026.218689_bib67","doi-asserted-by":"crossref","DOI":"10.1093\/bjs\/znaf281","article-title":"Circulating tumour DNA in patients with stage III colon cancer: Multicentre prospective PROVENC3 study","volume":"113","author":"Rubio-Alarc\u00f3n","year":"2025","journal-title":"Br. J. Surg."},{"issue":"6","key":"10.1016\/j.canlet.2026.218689_bib68","first-page":"987","article-title":"Tumor biomarkers in peripheral blood liquid biopsy of soft tissue sarcomas: research progress and clinical applications in the era of precision medicine","volume":"47","author":"Zhao","year":"2025","journal-title":"Zhongguo Yi Xue Ke Xue Yuan Xue Bao"},{"key":"10.1016\/j.canlet.2026.218689_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.116198","article-title":"Phase II trial of neoadjuvant camrelizumab and apatinib in resectable NSCLC: 3-year survival outcomes and dynamic circulating tumor DNA analyses","volume":"234","author":"Guo","year":"2026","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.canlet.2026.218689_bib70","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1158\/2767-9764.CRC-25-0452","article-title":"Copy-number aberrations in circulating tumor DNA enable diagnosis and risk stratification of pediatric neuroblastic tumors","volume":"6","author":"Tao","year":"2026","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.canlet.2026.218689_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114673","article-title":"Potassium channels, tumorigenesis and targeted drugs","volume":"162","author":"Xia","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.canlet.2026.218689_bib72","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2025.1697875","article-title":"Molecular roles of microRNA-21 and exosomal miR-21 in gastrointestinal cancers: diagnostic, therapeutic, and drug resistance insights","volume":"12","author":"Wang","year":"2025","journal-title":"Front. Mol. Biosci."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526004532?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526004532?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T02:15:49Z","timestamp":1785723349000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383526004532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":72,"alternative-id":["S0304383526004532"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218689","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Orthogonally targeted tumor radiosensitization using cell penetrating peptide-ATM inhibitor conjugates to stimulate anti-tumor immune responses","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218689","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"218689"}}